Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC
Category: #health  By Nikita Chaurasia  Date: 2020-03-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC

Esperion Therapeutics, a US-based public pharmaceutical company, reportedly unveiled that two pooled data analyses from its 4 Phase 3 clinical studies of NEXLETOL and outcomes from Phase 2 trial of NEXLIZET were showcased during the ACC.20/WCC.

In a poster session that was showcased by Harold E Bays, FOMA, MD, FTOS, FACE, FTOS, FNLA, FACC., it was highlighted that in Phase 2 trial, NEXLIZET lowered LDL-C significantly by a 40% mean as compared placebo, lowered hsCRP by 25% in comparison to the baseline, and further did not worsen glycemic control.

Along with the first poster, an additional poster session was conducted by Eric S. G. Stroes, MD., PhD. This poster signified that inside the pooled Phase 3 trials, NEXLETOL substantially decreased hsCRP in patients suffering from hypercholesterolemia irrespective of the intensity or presence of background statin treatment.

The third and final poster session was conducted by Maciej Banach, Ph.D., FESC, FAHA, MD. In the session it was highlighted that in Phase 3, NEXLETOL facilitated significant additional lowering of LDL-C while also significantly lowering other lipid endpoints, irrespective of background ezetimibe presence. Most notably, NEXLETOL’s safety profile was similar without or with background ezetimibe treatment.

Tim Mayleben, President and the Chief Executive Officer of Esperion stated that the company is thrilled with the final outcomes of Phase 2 trials that signifies NEXLIZET gained a 40 percent LDL-C lowering, a substantial 25 percent decrease in hsCRP and did not exacerbate glycemic control in patients suffering from Type 2 diabetes. The pooled analyses from Phase 3 LDL-C decreasing development program shows that NEXLETOL can be safely integrated with multiple LDL-C medicines, crucial to aid more patients to achieve their LDL-C objectives.

Mayleben further added that these analyses assure the safety and efficacy of the company’s medicines for millions of patients wanting to decrease their bad cholesterol levels.

 

Source credit: https://www.esperion.com/investors-media/press-releases/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Emirates could slash 30,000 jobs to lower cost during COVID-19 crisis
Emirates could slash 30,000 jobs to lower cost during COVID-19 crisis
By Nikita Chaurasia

Emirates Group has reportedly been planning to lay off around 30,000 jobs in order to lower the cost amid the pandemic outbreak, that will soon bring the total number of employees working by nearly 30% from over 105,000 close to March-end. Apparentl...

Apple acquires live event recording and VR broadcaster NextVR
Apple acquires live event recording and VR broadcaster NextVR
By Nikita Chaurasia

Apple has recently confirmed that it has acquired NextVR, which is a virtual reality startup that specializes in recording live events such as sports matches and concerts for  VR experience. The announcement made by the company came after the pu...

Grant worth $6mn introduced in Singapore to support FinTech companies
Grant worth $6mn introduced in Singapore to support FinTech companies
By Nikita Chaurasia

The recent coronavirus pandemic has largely affected umpteen businesses globally. In a bid to help Fintech companies meet their day-to-day expenses, the Monetary Authority of Singapore (MAS), has established the FinTech Solidarity Grant that would pr...